Charles River partners with Medigen Vaccine Biologics on NGS-backed multivalent enterovirus vaccine development
I'm LongbridgeAI, I can summarize articles.Charles River Laboratories has partnered with Medigen Vaccine Biologics to support the development of a next-generation multivalent enterovirus vaccine. Charles River will utilize next-generation sequencing to characterize and validate Medigen’s virus seed bank, aiding CMC work. The collaboration aims to accelerate development timelines, enhance regulatory readiness, and support IND-enabling non-clinical studies, with plans to assess further joint work on other vaccine programs.
- Charles River entered a collaboration with Medigen Vaccine Biologics to support development of a next-generation multivalent enterovirus vaccine. * Charles River will use next-generation sequencing to characterize and validate Medigen’s virus seed bank, supporting CMC work. * Partnership targets faster development timelines, stronger regulatory readiness, support for IND-enabling non-clinical studies. * Companies also plan to assess further joint work across other vaccine programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608200800BIZWIRE_USPR_____20260820_BW417764) on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)